Acetaminophen-induced hepatotoxicity in rats is correlated with the accumulation of bile acids: an underlying mechanism

doi:10.5246/jcps.2018.07.051

Abstract

Abstract:

In the present study, we aimed to investigate the underlying mechanism of acetaminophen (APAP)-induced hepatotoxicityby measuring the expression levels of liver transporters and concentrations of bile acids (BAs) in rat plasma and liver. SD rats (42)were randomly assigned into six groups, including 6-h control group, APAP 6-h group, 12-h control group, APAP 12-h group, 24-h control group and APAP 24-h group. The estimation study of BAs in plasma and liver was performed on LC-MS/MS.The levels of bile salt export pump (Bsep), multidrug resistant protein 2 (Mrp2), multidrug resistant protein 4 (Mrp4), Na⁺/taurocholate cotransporting polypeptide (Ntcp) and organic anion transporting polypeptide 2 (Oatp2) in the liver were analyzed by Western blotting analysis. Compared with the corresponding control groups, no difference was found in the BA levels and the expressions of BA transporters in the plasma and liver after 6 h of APAP administration. While BA levels were significantly decreased in the plasma and increased in the liver after 12 h of APAP administration (P<0.05); and the expressions of Bsep and Mrp2 were significantly reduced (P<0.05). After 24 h of APAP administration, BA levels were both greatly increased in the plasma and liver (P<0.05); and the expressions of Mrp4 and Oatp2 were significantly decreased (P<0.05). In response to over-dose APAP, Bsep, Mrp2, Mrp4 and Oatp2 levels were reduced at different time points, causing the accumulation of BAs, and such accumulation may ultimately lead to the severe liver injury, which could be an underlying mechanism of the APAP-induced hepatotoxicity.

Key words: Acetaminophen, Hepatotoxicity, Bile acids, Hepatobiliary transporter

CLC Number:

R963

Supporting:

Yongwen Jin, Zhi Rao, Yanfang Wu, Guoqiang Zhang, Axi Shi, Yuhui Wei, Xin’an Wu. Acetaminophen-induced hepatotoxicity in rats is correlated with the accumulation of bile acids: an underlying mechanism[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(7): 498-509.

References

[1] Danan, G.; Teschke, R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int. J. Mol. Sci. 2015, 17, 14.

[2] Shah, F.; Medvedev, A.; Wassermann, A.M.; Brodney, M.; Zhang, L.; Makarov, S.; Stanton, R.V. The Identification of Pivotal Transcriptional Factors Mediating Cell Responses to Drugs With Drug-Induced Liver Injury Liabilities. Toxicol. Sci. 2018, 162, 177-188.

[3] Schuster, D.; Laggner, C. Why drugs fail-a study on side effects in new chemical entities. Curr. Pharm. Des. 2005, 11, 3545-3559.

[4] Wagner, M.; Zollner, G. New molecular insights into the mechanisms of cholestasis. J. Hepatol. 2009, 51, 565-580.

[5] Anderson, N.; Borlak, J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Toxicol. Sci. 2008, 60, 311-357.

[6] Jaeschke, H.; Gores, G.J. Mechanisms of hepatotoxicity. Toxicol. Sci. 2002, 65, 166-176.

[7] Jaeschke, H.; McGill, M.R. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab. Rev. 2012, 44, 88-106.

[8] van Beusekom, C.D.; van den Heuvel, J.J. The feline bile salt export pump: a structural and functional comparison with canine and human Bsep/BSEP. BMC Vet. Res. 2013, 9, 259.

[9] Perez, M.J.; Briz, O. Bile-acid-induced cell injury and protection. World J. Gastroenterol. 2009, 15, 1677-1689.

[10] Beuers, U.; Hohenester, S. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology. 2010, 52, 1489-1496.

[11] Hohenester, S.; Wenniger, L.M. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 2012, 55, 173-183.

[12] Shah, A.D.; Wood, D.M. Understanding lactic acidosis in paracetamol (acetaminophen) poisoning. Br. J. Clin. Pharmacol. 2011, 71, 20-28.

[13] Bunchorntavakul, C.; Reddy, K.R. Acetaminophen-related hepatotoxicity. Clin. Liver Dis. 2013, 17, 587-607.

[14] Ostapowicz, G.; Fontana, R.J. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 2002, 137, 947-954.

[15] Tan, S.C.; New, L.S. Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine. Toxicol. Lett. 2008, 180, 174-181.

[16] Dahlin, D.C.; Miwa, G.T. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. USA. 1984, 81, 1327-1331.

[17] Chen, W.; Koenigs, L.L. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem. Res. Toxicol. 1998, 11, 295-301.

[18] Aleksunes, L.M.; Slitt, A.L. Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol. Appl. Pharmacol. 2008, 226, 74-83.

[19] Ghanem, C.I.; Ruiz, M.L. Shift from biliary to urinary elimination of acetaminophen-glucuronide in aceta-minophen-pretreated rats. J. Pharmacol. Exp. Ther. 2005, 315, 987-995.
[20] Aleksunes, L.M.; Slitt, A.M. Differential expression of mouse hepatic transporter genes in response to aceta-minophen and carbon tetrachloride. Toxicol. Sci. 2005, 83, 44-52.

[21] Aleksunes, L.M.; Scheffer, G.L. Coordinated expression of multidrug resistance-associated proteins (Mrps) in mouse liver during toxicant-induced injury. Toxicol. Sci. 2006, 89, 370-379.

[22] Jin, Y.W.; Rao, Z. Development of a LC-MS/MS Method for Simultaneous Determination of Bile Acids and their Conjugates in Hepatocytes, Tissue and Fluids in Rat. Curr. Pharm. Anal. 2018, 14, 331-341.

[23] McJunkin, B.; Barwick, K.W. Fatal massive hepatic necrosis following acetaminophen overdose. JAMA. 1976, 236, 1874-1875.

[24] Larson, P.A.; Janower, M.L. The nighthawk: bird of paradise or albatross? J. Am. Coll. Radiol. 2005, 2, 967-970.

[25] Alkiyumi, S.S.; Abdullah, M.A. Ipomoea aquatica extract shows protective action against thioacetamide-induced hepatotoxicity. Molecules. 2012, 17, 6146-6155.

[26] James, A.P.; Slivkoff-Clark, K. Ipomoea aquatica extract shows protective action against thioacetamide-induced hepatotoxicity. Asia Pac. J. Public. Health. 2003, 15, 37-40.

[27] Jaeschke. H. Are cultured liver cells the right tool to investigate mechanisms of liver disease or hepatotoxicity? Hepatology. 2003, 38, 1053-1055.

[28] Hinson, J.P.; Khan, M. Dehydroepiandrosterone sulphate (DHEAS) inhibits growth of human vascular endothelial cells. Endocr. Res. 2004, 30, 667-671.

[29] Kon, T.; Tanigawa, T. Singlet oxygen quenching activity of human serum. Redox Rep. 2004, 9, 325-330.

[30] Chen, C.; Krausz, K.W. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem. Res. Toxicol. 2009, 22, 699-707.

[31] Hylemon, P.B.; Zhou, H. Bile acids as regulatory molecules. J. Lipid Res. 2009, 50, 1509-1520.

[32] Perez, M.J.; Briz, O. Bile-acid-induced cell injury and protection. World J. Gastroenterology. 2009, 15, 1677-1689.

[33] Copple, B.L.; Jaeschke, H. Oxidative stress and the pathogenesis of cholestasis. Semin. Liver Dis. 2010, 30, 195-204.

[34] Luo. L.; Schomaker, S. Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents. Toxicol. Sci. 2014, 137, 12-25.

[35] Alnouti, Y.; Csanaky, I.L. Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 873, 209-217.

[36] Deo, A.K.; Bandiera, S.M. Biotransformation of lithocholic acid by rat hepatic microsomes: metabolite analysis by liquid chromatography/mass spectrometry. Drug Metab. Dispos. 2008, 36, 442-451.

[37] Rolo, A.P.; Oliveira, P.J. Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol. Sci. 2000, 57, 177-185.

[38] Javitt, N.B.; Emerman, S. Effect of sodium taurolithocholate on bile flow and bile acid exeretion. J. Clin. Invest. 1968, 47, 1002.

[39] Fischer, C.; Cooper, N.; Rothschild, M.; Mosbach, E. Effect of dietary chenodeoxycholic acid and lithocholic acid in the rabbit. Dig. Dis. Sci. 1974, 19, 877-886.

[40] Delzenne, N.M.; Calderon, P.B. Comparative hepatotoxicity of cholic acid, deoxycholic acid and lithocholic acid in the rat: in vivo and in vitro studies. Toxicol. Lett. 1992, 61, 291-304.

[41] Palmer, A. Heywood, R. Pathological changes in the rhesus fetus associated with the oral administration of chenodeoxycholic acid. Toxicology. 1974, 2, 239-246.

[42] Dyrszka, H.; Salen, G. Pathological changes in the rhesus fetus associated with the oral administration of chenodeoxycholic acid. Gastroenterology. 1976, 70, 93.

[43] Song, P.; Zhang, Y. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice. Toxicol. Sci. 2011, 123, 359-367.

[44] Woolbright, B.L.; McGill, M.R. Acute Liver Failure Study Group. Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients. Toxicol. Sci. 2014, 142, 436-444.

[45] Rodrigues, C.M.; Stieers, C.L. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J. Neurochem. 2000, 75, 2368-2379.

[46] Trauner, M.; Boyer, J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 2003, 83, 633-671.

[47] Lorbek, G.; Lewinska, M. Cytochrome P450s in the synthesis of cholesterol and bile acids--from mouse models to human diseases. FEBS J. 2012, 279, 1516-1533.
[48] Trottier, J.; Białek, A. Profiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting. PLoS One. 2011, 6, e22094.